Eventide Asset Management - Q3 2023 holdings

$5.56 Billion is the total value of Eventide Asset Management's 155 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 45.0% .

 Value Shares↓ Weighting
TT BuyTRANE TECHNOLOGIES PLC$160,424,704
+6.3%
790,620
+0.2%
2.88%
+13.0%
ZNTL BuyZENTALIS PHARMACEUTICALS INC$156,749,622
-19.2%
7,814,039
+13.6%
2.82%
-14.1%
FLYW BuyFLYWIRE CORPORATION$129,832,737
+2.8%
4,071,268
+0.1%
2.33%
+9.3%
EXAS BuyEXACT SCIENCES CORP$127,438,371
-27.3%
1,868,050
+0.0%
2.29%
-22.7%
MIRM BuyMIRUM PHARMACEUTICALS INC$125,091,097
+39.8%
3,958,579
+14.4%
2.25%
+48.7%
ROP BuyROPER TECHNOLOGIES INC$114,826,178
+0.8%
237,107
+0.1%
2.06%
+7.3%
POOL BuyPOOL CORP$102,235,954
-3.2%
287,099
+1.9%
1.84%
+3.0%
CRWD BuyCROWDSTRIKE HLDGS INCcl a$83,588,568
+14.4%
499,394
+0.4%
1.50%
+21.7%
DHI BuyD R HORTON INC$80,730,819
-3.6%
751,194
+9.1%
1.45%
+2.5%
HZNP BuyHORIZON THERAPEUTICS PUB L$79,795,095
+12.5%
689,732
+0.0%
1.43%
+19.6%
TTD BuyTHE TRADE DESK INC$79,137,972
+1.8%
1,012,642
+0.6%
1.42%
+8.2%
XMTR BuyXOMETRY INC$74,021,135
+9.5%
4,359,313
+36.6%
1.33%
+16.5%
LAD BuyLITHIA MTRS INC$73,098,310
-1.6%
247,514
+1.3%
1.31%
+4.6%
EVH BuyEVOLENT HEALTH INCcl a$71,858,336
-10.1%
2,638,940
+0.0%
1.29%
-4.4%
SWAV BuySHOCKWAVE MED INC$70,823,255
+2.3%
355,717
+46.7%
1.27%
+8.8%
COUR BuyCOURSERA INC$69,039,178
+55.9%
3,693,910
+8.6%
1.24%
+65.7%
DDOG BuyDATADOG INC$66,580,687
+36.5%
730,933
+47.4%
1.20%
+45.3%
COLL BuyCOLLEGIUM PHARMACEUTICAL INC$58,810,315
+4.0%
2,631,334
+0.0%
1.06%
+10.6%
BuyTOAST INCcl a$54,805,366
+51.4%
2,926,074
+82.4%
0.98%
+60.9%
TREX BuyTREX CO INC$54,390,324
-6.0%
882,530
+0.0%
0.98%0.0%
ASND BuyASCENDIS PHARMA A/Ssponsored adr$53,884,014
+4.9%
575,438
+0.0%
0.97%
+11.5%
DV BuyDOUBLEVERIFY HLDGS INC$53,678,758
-26.8%
1,920,528
+1.9%
0.96%
-22.2%
TMDX BuyTRANSMEDICS GROUP INC$50,663,241
+794.3%
925,356
+1271.7%
0.91%
+849.0%
LNG BuyCHENIERE ENERGY INC$49,989,641
+8.9%
301,215
+0.0%
0.90%
+15.7%
TRGP BuyTARGA RES CORP$49,259,341
+65.2%
574,654
+46.7%
0.88%
+75.6%
MPWR BuyMONOLITHIC PWR SYS INC$45,425,688
-13.6%
98,324
+1.0%
0.82%
-8.2%
FIVN BuyFIVE9 INC$44,627,608
-21.9%
694,053
+0.1%
0.80%
-17.0%
CLDX BuyCELLDEX THERAPEUTICS INC NEW$44,032,000
-5.8%
1,600,000
+16.1%
0.79%
+0.1%
ASML BuyASML HOLDING N V$41,142,036
-18.1%
69,891
+0.9%
0.74%
-13.0%
LSCC BuyLATTICE SEMICONDUCTOR CORP$36,778,298
-10.5%
428,003
+0.0%
0.66%
-4.9%
BuyMARINUS PHARMACEUTICALS INC$36,466,476
+5.8%
4,529,997
+42.8%
0.66%
+12.5%
SNPS BuySYNOPSYS INC$36,260,925
+6.5%
79,005
+1.0%
0.65%
+13.2%
MNDY NewMONDAY COM LTD$32,419,899203,617
+100.0%
0.58%
KLAC BuyKLA CORP$30,746,273
+4.4%
67,035
+10.4%
0.55%
+11.0%
CRNX BuyCRINETICS PHARMACEUTICALS IN$30,298,577
+286.7%
1,018,782
+134.3%
0.54%
+312.9%
ORLY BuyOREILLY AUTOMOTIVE INC$27,931,086
-4.0%
30,732
+1.0%
0.50%
+2.2%
SGEN BuySEAGEN INC$27,789,529
+10.2%
130,990
+0.0%
0.50%
+17.1%
BuyAURA BIOSCIENCES INC$27,133,398
-25.2%
3,024,905
+3.0%
0.49%
-20.4%
FANG BuyDIAMONDBACK ENERGY INC$26,283,601
+75.9%
169,703
+49.2%
0.47%
+86.6%
AKRO BuyAKERO THERAPEUTICS INC$25,991,848
+46.8%
513,876
+35.5%
0.47%
+56.2%
INSP BuyINSPIRE MED SYS INC$24,822,860
-29.3%
125,090
+15.6%
0.45%
-24.9%
AJG BuyGALLAGHER ARTHUR J & CO$24,743,853
+15.5%
108,559
+11.2%
0.44%
+22.9%
AXSM NewAXSOME THERAPEUTICS INC$24,231,702346,712
+100.0%
0.44%
FERG NewFERGUSON PLC NEW$24,012,949146,002
+100.0%
0.43%
SHW BuySHERWIN WILLIAMS CO$23,749,491
-2.9%
93,117
+1.1%
0.43%
+3.4%
ISRG BuyINTUITIVE SURGICAL INC$22,330,664
-13.0%
76,399
+1.8%
0.40%
-7.6%
PNR BuyPENTAIR PLC$21,383,688
+0.2%
330,250
+0.0%
0.38%
+6.4%
DVAX BuyDYNAVAX TECHNOLOGIES CORP$21,047,250
+58.8%
1,425,000
+38.9%
0.38%
+68.8%
PCVX NewVAXCYTE INC$20,035,140393,000
+100.0%
0.36%
BILL NewBILL HOLDINGS INC$19,891,544183,214
+100.0%
0.36%
BEPC BuyBROOKFIELD RENEWABLE CORPcl a sub vtg$18,581,079
-24.0%
776,152
+0.0%
0.33%
-19.1%
ROL NewROLLINS INC$18,303,944490,328
+100.0%
0.33%
NOVT BuyNOVANTA INC$18,077,456
-22.1%
126,028
+0.0%
0.32%
-17.1%
CMS BuyCMS ENERGY CORP$17,598,423
-6.8%
331,358
+3.1%
0.32%
-0.9%
HLI NewHOULIHAN LOKEY INCcl a$16,028,580149,632
+100.0%
0.29%
RPHM BuyRENEO PHARMACEUTICALS INC$15,825,051
+37.8%
2,078,142
+18.8%
0.28%
+46.4%
VRNA NewVERONA PHARMA PLCsponsored ads$13,855,000850,000
+100.0%
0.25%
ESI BuyELEMENT SOLUTIONS INC$13,408,926
+16.7%
683,780
+14.2%
0.24%
+24.2%
INZY NewINOZYME PHARMA INC$13,125,0003,125,000
+100.0%
0.24%
BuyGXO LOGISTICS INCORPORATED$12,913,264
-6.6%
220,175
+0.0%
0.23%
-0.9%
EQT NewEQT CORP$12,831,396316,200
+100.0%
0.23%
DNLI BuyDENALI THERAPEUTICS INC$12,828,766
+38.7%
621,850
+98.4%
0.23%
+48.1%
EGP BuyEASTGROUP PPTYS INC$11,066,585
+91.7%
66,454
+99.8%
0.20%
+103.1%
ARDX NewARDELYX INC$10,995,6002,695,000
+100.0%
0.20%
RVMD BuyREVOLUTION MEDICINES INC$9,992,480
+3.6%
361,000
+0.1%
0.18%
+10.4%
FREQ NewFREQUENCY THERAPEUTICS INC$9,999,9993,597,122
+100.0%
0.18%
IDYA NewIDEAYA BIOSCIENCES INC$9,038,300335,000
+100.0%
0.16%
INBX NewINHIBRX INC$7,964,377434,026
+100.0%
0.14%
EQIX BuyEQUINIX INC$7,702,714
+3.2%
10,606
+11.4%
0.14%
+9.5%
ANAB NewANAPTYSBIO INC$7,668,920427,000
+100.0%
0.14%
GPI NewGROUP 1 AUTOMOTIVE INC$4,630,14217,231
+100.0%
0.08%
VST NewVISTRA CORP$3,753,919113,138
+100.0%
0.07%
INTA NewINTAPP INC$2,882,15085,983
+100.0%
0.05%
NewTURNSTONE BIOLOGICS CORP$2,790,769708,317
+100.0%
0.05%
BuyARTERIS INC$2,597,640
-4.5%
399,023
+0.1%
0.05%
+2.2%
MDB NewMONGODB INCcl a$2,521,6657,291
+100.0%
0.04%
PXD NewPIONEER NAT RES CO$1,592,6186,938
+100.0%
0.03%
NOW BuySERVICENOW INC$811,051
+59.3%
1,451
+60.2%
0.02%
+66.7%
ALV NewAUTOLIV INC$815,2568,450
+100.0%
0.02%
SPGI NewS&P GLOBAL INC$831,3082,275
+100.0%
0.02%
SHOP NewSHOPIFY INCcl a$729,60113,370
+100.0%
0.01%
EW BuyEDWARDS LIFESCIENCES CORP$678,528
+40.8%
9,794
+91.7%
0.01%
+50.0%
NewLINDE PLC$684,7521,839
+100.0%
0.01%
ALGN BuyALIGN TECHNOLOGY INC$587,741
+41.1%
1,925
+63.4%
0.01%
+57.1%
TSM BuyTAIWAN SEMICONDUCTOR MFG LTDsponsored ads$595,178
+62.0%
6,849
+88.2%
0.01%
+83.3%
WM NewWASTE MGMT INC DEL$483,6923,173
+100.0%
0.01%
ZTS NewZOETIS INCcl a$389,0192,236
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings